Ingevity is no longer the sprawling pine-chemicals company that left WestRock a decade ago. Management has spent the first half of the year selling the industrial specialties line and the road markings business, paying the long-running BASF judgment in cash, and putting the caprolactone unit on the block. What remains is a high-margin activated-carbon franchise tied to gasoline vapor canisters, plus a smaller pavement-additives business. The second-quarter print is the first clean look at that slimmer company, and the market is still treating the equity as a turnaround rather than a finished specialty-materials story.
Adjusted earnings before interest, taxes, depreciation, and amortization from continuing operations rose to $115 million. That is a mid-thirties margin on a sales base that declined only because Road Markings left in mid-April. The carbon segment still delivers more than half of that profit at a mid-fifties margin, helped by hybrid vehicles that need more sophisticated canisters than battery-only cars. The cash story is messier. Operating cash went negative in the first half after a $113 million BASF payment. The company still bought back stock and cut net leverage to two and a half times trailing adjusted earnings.
Management raised the full-year adjusted earnings range after the print and still includes Advanced Polymer Technologies in the outlook with no assumed sale proceeds. The open questions are whether hybrid mix keeps carbon margins in the mid-fifties after planned plant outages, whether the polymer sale closes at a price that matches the fresh write-down, and whether the remaining stranded costs from the exited lines come out before year-end. Those three variables decide if the current multiple is paying for a finished company or for a still-messy transition.